France's Abivax H1 net loss widens on higher expenses driven by clinical programs

Abivax SA

21/09/2026 21:27

Overview
France biotechnology firm's H1 2026 net loss widened as operating expenses increased
Company completed royalty certificate buy-back, reducing royalty overhang and strengthening debt-free position
Abivax raised €767.1 mln in July public offering, extending cash runway into Q4 2029

Outlook
Abivax projects cash runway into Q4 2029 based on current operating assumptions
Company plans NDA submission for obefazimod in ulcerative colitis by end of 2026
Abivax expects topline results from Phase 2b Crohn’s disease trial in mid-2027

Result Drivers
R&D EXPANSION - Higher R&D expenses driven by expanded clinical programs and preparations for potential commercialization of obefazimod
INFRASTRUCTURE INVESTMENT - G&A expenses rose due to personnel costs, share-based compensation, and consulting fees for building commercial infrastructure
COMMERCIAL PREPARATION - Sales and marketing expenses increased as company prepared for potential future sales and commercialization of obefazimod in the U.S.

Company press release: ID:nGNX8GSJwt

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Net Loss
 
EUR 165.90 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Abivax SA is €165.00, about 82% above its September 21 closing price of €90.65

Reuters Recommended Reads
Sept 18 - Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Sept 21 - Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion
Sept 21 - Drug developer ADARx seeks $1.74 billion valuation in US IPO

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)